Endothelial growth factor therapy improves preeclampsia-like manifestations in a murine model induced by overexpression of sVEGFR-1

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 301, Issue 5, 2011, Pages

  Mateus, Julio ^a   Bytautiene, Egle ^a   Lu, Fangxian ^a   Tamayo, Esther H ^a   Betancourt, Ancizar ^a   Hankins, Gary D V ^a   Longo, Monica ^a   Saade, George R ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Hypertension; Soluble vascular endothelial growth factor receptor 1; Vascular dysfunction

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ACETYLCHOLINE; IMMUNOGLOBULIN FRAGMENT; NITROPRUSSIDE SODIUM; PHENYLEPHRINE; VASCULOTROPIN 121; VASCULOTROPIN RECEPTOR 1;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MONITORING; BODY WEIGHT; CAROTID ARTERY; CATHETER; CONTROLLED STUDY; EUTHANASIA; INTRAUTERINE GROWTH RETARDATION; ISOMETRIC EXERCISE; ISOMETRICS; MOUSE; MUSCLE CONTRACTILITY; MYOGRAPHY; NONHUMAN; OSMOTIC PUMP; PLACENTA; PREECLAMPSIA; PREGNANCY; PRENATAL GROWTH; PRIORITY JOURNAL; VASCULAR DISEASE; VASODILATATION;

ADENOVIRIDAE; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FETAL GROWTH RETARDATION; FETAL WEIGHT; GENETIC VECTORS; GESTATIONAL AGE; INFUSION PUMPS, IMPLANTABLE; INFUSIONS, SUBCUTANEOUS; MICE; PRE-ECLAMPSIA; PREGNANCY; RECOMBINANT PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VASODILATION; VASODILATOR AGENTS;

EID: 80355128996     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00373.2011     Document Type: Article

References (42)

1. Bergmann A, Ahmad S, Cudmore M, Gruber AD, Wittschen P, Lindenmajer W, Christofori G, Gross V, Gonzalves ACH, Gröne HJ, Ahmed A, Weigh HA. Reduction of circulating soluble sFlt-1 alleviates preeclampsia-like symptoms in a mouse model. J Cell Mol Med 14: 1857-1867, 2010.
2. Bridges JP, Gilbert JS, Colson D, Gilbert SA, Dukes MP, Ryan MJ, Granger JP. Oxidative stress contributes to soluble Fms-like tyrosine kinase-1 induced vascular dysfunction in pregnant rats. Am J Hypertens 22: 564-568, 2009.
3. Dekker G, Robillard PY. The birth interval hypothesis-does it really indicate the end of the primipaternity hypothesis? J Reprod Immunol 59: 245-251, 2003.
4. Dekker GA, Sibai BM. Etiology and pathogenesis of preeclampsia: current concepts. Am J Obstet Gynecol 179: 1359-1375, 1998.
5. Fernando NH, Hurwitz HI. Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. Semin Oncol 30: 39-50, 2003.
6. Ferrara N, Gerber HP, Lecouter J. The biology of VEGF and its receptors. Nat Med 9: 669-676, 2003.
7. Genbacev O, DiFederico E, McMaster M, Fisher SJ. Invasive cytotro-phoblast apoptosis in pre-eclampsia. Hum Reprod 14: 59-66, 1999.
8. Gilbert JS, Babcock SA, Granger JP. Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase-1 expression. Hypertension 50: 1142-1147, 2007.
9. Gilbert JS, Verzwyvelt J, Colson D, Arany M, Karumanchi SA, Granger JP. Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placental ischemia-induced hypertension. Hypertension 55: 380-385, 2010.
10. Guba M, Seeliger H, Kleespies A, Jauch KW, Bruns C. Vascular endothelial growth factor in colorectal cancer. Int J Colorectal Dis 19: 510-517, 2004.
11. Hertig A, Berkane N, Lefevre G, Toumi K, Marti HP, Capeau J, Uzan S, Rondeau E. Maternal serum sFlt-1 concentration is an early and reliable predictive marker of preeclampsia. Clin Chem 50: 1702-1703, 2004.
12. Kanasaki K, Palmsten K, Sugimoto H, Ahmad S, Hamano Y, Xie L, Parry S, Augustin HG, Gattone VH, Folkman J, Strauss JF, Kalluri R. Deficiency in catechol-O-methyltransferase and 2-methoxyestradiol is associated with pre-eclampsia. Nature 453: 1117-1121, 2008.
13. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 90: 10705-10709, 1993.
14. Kendall RL, Wang G, Thomas KA. Identification of a natural soluble form of the vascular endothelial growth factor receptor. FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 226: 324-328, 1996.
15. Khalil A, Muttukrishna S, Harrington K, Jauniaux E. Effect of antihypertensive therapy with alpha methyldopa on levels of angiogenic factors in pregnancies with hypertensive disorders. PLoS One 3: E2766, 2008.
16. Kim KJ, Li B, Winer J, Armanini M, Gillet N, Phillips HS, Ferrara N. Inhibition of vascular endothelial growth factor induced angiogenesis suppresses tumour growth in vivo. Nature 362: 841-844, 1993.
17. Kleespies A, Guba M, Jauch KW, Bruns CJ. Vascular endothelial growth factor in esophageal cancer. J Surg Oncol 87: 95-104, 2004.
18. Leonard EC, Friedrich JL, Basile DP. VEGF-121 preserves renal microvessel structure and ameliorates secondary renal disease following acute kidney injury. Am J Physiol Renal Physiol 295: F1648-F1657, 2008.
19. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350: 672-683, 2004.
20. Lewis SJ, Travis MD, Hasmi-Hill MP, Sandock K, Robertson TP, Bates JN. Differential effects of ouabain on the vasodilator actions of nitric oxide and S-nitrosothiols in vivo: relevance to the identity of EDRH/EDHF. Vascul Pharmacol 45: 383-394, 2006.
21. Li Z, Zhang Y, Ying Ma J, Kapoun AM, Shao Q, Kerr I, Lam A, O'Young G, Sannajust F, Stathis P, Schreiner G, Karumanchi SA, Potter AA, Pollitt NS. Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension 50: 686-692, 2007.
22. Lu F, Longo M, Tamayo E, Maner W, Al-Hendy A, Anderson GD, Hankins GD, Saade GR. The effect of over-expression of sFlt-1 on blood pressure and the occurrence of other manifestations of preeclampsia in unrestrained conscious pregnant mice. Am J Obstet Gynecol 196: 396.e1- e7, 2007.
23. Makris A, Thornton C, Thompson J, Thomson S, Martin R, ogle R, Waugh R, McKenzie P, Kirwan P, Hennessy A. Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. Kidney Int 71: 977-984, 2007.
24. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Liber-mann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. Excess placental soluble fms- like tyrosine kinase 1 (sFlt-1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111: 649-658, 2003.
25. McKeeman GC, Ardill JE, Caldwell CM, Hunter AJ, McClure N. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. Am J Obstet Gynecol 191: 1240-1246, 2004.
26. Pijnenborg R, Robertson WB, Brosens I, Dixon G. Trophobast invasion and the establishment of haemochorial placentation in man and laboratory animals. Placenta 2: 71-91, 1981.
27. Posey JA, Ng TC, Yang B, Khazaeli MB, Carpenter MD, Fox F, Needle M, Waksal H, LoBuglio AF. A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. Clin Cancer Res 9: 1323-1332, 2003.
28. Prewett M, Huber J, Li Y, Santiago A, O'Connor W, King K, Overholser J, Hooper A, Pytowski B, Witte L, Bohlen P, Hicklin DJ. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 59: 5209-5218, 1999.
29. Rajagopalan S, Shah M, Luciano A, Crystal R, Nabel EG. Adenovirus-mediated gene transfer of VEG121 improves extremity endothelial function and flow reverse. Circulation 104: 753-755, 2001.
30. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science 308: 1592-1594, 2005.
31. Rinkenberg J, Werb Z. The labyrinthine placenta. Nat Genet 25: 248-250, 2000.
32. Roberts JM, Hubel CA. Oxidative stress in preeclampsia. Am J Obstet Gynecol 190: 1177-1178, 2004.
33. Rossant J, Cross JC. Placental development: lessons from mouse mutants. Nat Rev Genet 2: 538-548, 2001.
34. Sanc DC, Anton L, Brosnihan KB. Angiogenic growth factors and hypertension. Angiogenesis 7: 193-201, 2004.
35. Scotland RS, Madhani M, Chauhan S, Moncada S, Andresen J, Nilsson H, Hobbs AJ, Ahluwalia A. Investigation of vascular responses in endothelial nitric oxide synthase/cyclooxygenase-1double knockout mice: key role of endothelium-derived hyperpolarizing factor in the regulation of blood pressure in vivo. Circulation 111: 796-803, 2005.
36. Sibai B, Dekker G, Kupferminc M. Preeclampsia. Lancet 365: 785-799, 2005.
37. Suga SI, Kim YG, Joly A, Puchacz E, Kang DH, Jefferson JA, Abraham JA, Hughes J, Johnson RJ, Schreiner GF. Vascular endo-thelial growth factor (VEGF121) protects rats from renal infarction in thrombotic microangiopathy. Kidney Int 60: 1297-1308, 2001.
38. Tonini T, Rossi F, Claudio PP. Molecular basis of angiogenesis and cancer. Oncogene 22: 6549-6556, 2003.
39. Wathen KA, Tuutti E, Stenman UH, Alfthan H, Halmesmäkj E, Finne P, Ylikorkala O, Vuorela P. Maternal serum-soluble vascular endothelial growth factor receptor-1 in early pregnancy ending in preeclampsia and intrauterine growth restriction. J Clin Endocrinol Metab 91: 180-184, 2006.
40. Xu B, Thornton C, Tooher J, Ogle R, Lim S, Makris A, Hennessy A. Effects of anti-hypertensive drugs on production of soluble fms-like tyrosine kinase 1 and soluble endoglin from human normal and pre-eclamptic placentas in vitro. Clin Exp Pharmacol Physiol 36: 839-842, 2009.
41. Young BC, Levine RJ, Karumanchi SA. Pathogenesis of preeclampsia. Annu Rev Pathol 5: 173-192, 2010.
42. Zhou Y, McMaster M, Woo K, Janatpour M, Perry J, Karpanen T, Alitalo K, Damsky C, Fisher SJ. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol 160: 1405-1423, 2002.